Late Stage Autoimmune Pipeline Will Unlock Transformational Long Term Upside

AnalystHighTarget

Analyst High Target compiles bullish analysts opinions to create narratives which represent one standard deviation above the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls

Published

14 Dec 25

Updated

06 Jul 26

Views

Not Invested

Shared on 06 Jul 26

Fair value Increased 39%

ROIV: Late Stage Pipeline Progress Will Shape Future Upside Potential

Wall Street analysts turn more optimistic on Roivant as fresh trial results and progress on key drug candidates lead them to raise what they think the business could be worth. The shift hinges on growing confidence in two late-stage programs and on upcoming regulators’ decisions that could change the company’s outlook.

3 views

Fair Value vs Share Price

US$45

vs US$34.5223.3% undervalued

686.8%

Revenue growth

29.9%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Roivant Sciences

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Flawless balance sheet with limited growth.

Market capUS$24.8b

PB5.5x

Estimated Growth54.0%

Dividend YieldN/A

Full analysis

CEO & management

Matthew Gline

CEO

4.5yrs

CEO Tenure

A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.